Rationale for transdermal drug administration in Alzheimer disease.
about
A practical algorithm for managing Alzheimer's disease: what, when, and why?Real-world evaluation of compliance and preference in Alzheimer's disease treatment.Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.New non-oral drug delivery systems for Parkinson's disease treatment.Drug delivery strategies for Alzheimer's disease treatment.Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson's disease.Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers.Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model.Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.Transdermal donepezil on the treatment of Alzheimer's disease.Hydroxypropylmethylcellulose films for prolonged delivery of the antipsychotic drug chlorpromazine.Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.Analysis of hair follicle penetration of lidocaine and fluorescein isothiocyanate-dextran 4 kDa using hair follicle-plugging method.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
P2860
Q26859831-387470FD-4C85-4318-AA4A-63C0FFE4191AQ36264977-23942492-7EF9-43F6-A677-5A090009F7F4Q36467267-92351030-538D-4252-8653-4DABAE78EF37Q37385577-67B98CF8-75BF-45F0-9654-FD03CBF07C30Q37764347-F357024D-F7A1-4BD5-955B-FAFC0B0A3400Q37840165-56565336-49EE-4271-A9D8-00EA790FCFB7Q37851509-757AF490-9CDD-4AB2-9AA9-146355F49CA8Q37895257-A353B933-BD89-43B5-84DF-0C26DEC3573BQ37952853-73EACEA5-3886-45FF-93FB-8936FC3D5478Q37997774-D4A9CEAD-4069-4A3E-8224-F89F0EE664FBQ38225721-91A4B97F-0664-4C81-A52B-624F88AD64C1Q38801735-18BC1D9C-161B-4403-A260-C8EF5B98E29EQ39168403-A2122AB7-E815-4FDB-992A-2381E4D210EBQ40899039-90054B4D-C6A9-43DC-8C25-D3FAEE7F6432Q40979821-7676FFAB-E8B9-43A5-AD3F-851904E27958Q41281485-7EB23FE0-C8F2-408E-B160-7AA249258721Q41786451-2903D555-CE7B-4EE0-8A81-2A5D285EDEA7Q43058457-2C23C341-BA49-412F-AA3F-AC53BC262D8DQ43609548-2F891805-B242-4436-B214-142A255AA09EQ46435119-C220DE34-35E2-4149-9162-168CB9D6A316Q51491144-5572EE5A-8FDD-4005-BDB7-608A536B884C
P2860
Rationale for transdermal drug administration in Alzheimer disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Rationale for transdermal drug administration in Alzheimer disease.
@en
type
label
Rationale for transdermal drug administration in Alzheimer disease.
@en
prefLabel
Rationale for transdermal drug administration in Alzheimer disease.
@en
P2093
P1433
P1476
Rationale for transdermal drug administration in Alzheimer disease.
@en
P2093
Georg Adler
Joel S Ross
Karla Eggert
P356
10.1212/01.WNL.0000281845.40390.8B
P407
P433
P577
2007-07-01T00:00:00Z